It’s a bit cryptic … From the quarterly on the 30th Jan it was...

It’s a bit cryptic …

From the quarterly on the 30th Jan it was said ….

“There were preliminary signs of efficacy from the 14 patients dosed in the Phase 1b trial.”

From today’s Ann …

Of these fourteen patients seven (7) patients remained on trial for >6 months, with two (2)
patients being on trial for more than 10 months.

Six (6) patients have now recorded a partial response as best response, with the remaining
eight (8) recording stable disease.

6 and 8 presumably that’s the 14 patients in question from 1b trail

No mention of any deaths …

These response rates are substantially higher than predicted from historical studies of
gemcitabine and Abraxane treatment alone.

And  importantly,  … Three (3) patients remain on trial from the Phase 1b cohort.

.